diálogos ELE

has decided to embark on the path of fine-tuning and developing rhNGF in its formulation for clinical use, at its own biotech facility in L’Aquila. and in Naples, where there are the laboratories of Drug Discovery and Technology Formulation, within a long-term collaboration with CNR. Italian excellence: the Dompé Hub in L’Aquila. Dompé has concentrated its manufacturing and research and development activities at its L’Aquila hub.

Author: Arajas Dara
Country: Lebanon
Language: English (Spanish)
Genre: Finance
Published (Last): 25 May 2010
Pages: 243
PDF File Size: 7.48 Mb
ePub File Size: 6.16 Mb
ISBN: 698-1-57877-276-5
Downloads: 35653
Price: Free* [*Free Regsitration Required]
Uploader: Tojalmaran

Reparixin oral tablets are being tested as a CSC targeting agent in patients with metastatic non- human epidermal growth factor receptor HER2 -amplified BC.

An audit trail system serves to register, in an inalterable manner, every operation carried out during processing. You are going to leave this site. Do you want to be redirected to the mobile version?

Our story | Dompé

The current annual production capacity is 50 million packs. We suggest you to update it for free by following one of the these links, choosing the browser you prefer: One group received Oxervate, a second group received an eye drop with a different concentration of cenegermin, and the third group received an eye drop without cenegermin.

The aim is to convey all the metabolic energy of the bacterium with a solely reproductive aim. Click here to continue reading.

Our research

Currently being tested in Phase II clinical trials, the drug is designed to counteract in an innovative way the inflammatory reactions that characterise the early stage of type 1 diabetes.

Accessing the website you have selected you will be subject to the terms of use of this last. The areas of activity are: DrugsOrganic ChemistryFda. The company still has its do,pe head offices in Milan. Cenegermin is a human beta-nerve growth factor beta-ngf – – peptide non-covalent dimer produced in escherichia coli. Several laboratories are up and running at CDMO, for analytical development and quality control, making it possible to conduct the most in-depth analyses in the biotechnology field.

  FUNDAMENTOS DE TERMODINAMICA GORDON J.VAN WYLEN PDF

L’Aquila hub

Follow Blog via Email Enter your email address to follow this blog and receive notifications of new posts by email. Discovered in the s by Nobel Prize winner Rita Levi Montalcini, NGF belongs to the neurotrophins, a family of proteins that can play a crucial role in regulating the survival, development and functions of neurons, both at a central and peripheral level. Accessing the website you have selected you will be subject to the terms of use of this last. The hub, which operates in compliance with GMP rules, is authorised to manufacture products using recombinant DNA technology, i.

In the first part of the downstream process, the inclusion bodies, coming from the upstream phase, are solubilised and then the folding phase starts. The fermentation phase lasts approximately three days, during which the bacterial cells multiply exponentially, also duplicating the gene for the production of proNGF.

The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after organ transplantion. The packaging is divided into two phases. The protein—in this case Nerve Growth Factor, NGF —is produced using a living organism the bacterium Escherichia Coli of which the entire genome and the complex of biological interactions is known in detail.

His friends call him Open superstar worlddrugtracker. Everything is monitored, from air quality to water quality to the pulverisation process.

Our research | Dompé

Post was not sent – check your email addresses! Cenegermin contains amino acids and has a relative molecular mass of 13, Daltons and the following molecular formula: Cenegermin August 23, 9: The collaborations in the territory have the objective of creating new knowledge and developing suitable expertise for the profound technological and innovative transformation that is revolutionizing the health sector worldwide.

The CDMO specialises in the production of therapeutic proteins, or recombinant vaccines, for human use. For information, including how to block the cookies, click here. In the first study, only patients with the disease in one eye were enrolled, while in the second study, patients with the disease in both eyes were treated in both eyes bilaterally. Reparixin is an inhibitor of CXCR1 and CXCR2 receptors activated by interleukin-8 IL-8a key chemotactic factor in the inflammatory reaction immediately following pancreatic islet transplantation in patients with type 1 diabetes.

  ASSEMBLAGE ENVIRONMENTS AND HAPPENINGS PDF

Regarded as among the world’s foremost experts on corneal diseases, he was appointed Adjunct Assistant Professor of Biology at Temple University of Philadelphia. The BF unit works mainly in the field of ophthalmology with the aim of optimising the periocular and intraocular release of proteins, for the treatment of rare diseases. From Italy to the formulqtion During the granulation phase the active ingredient and the excipients are bonded until they become granules, which, in turn, are finally coated in excipients in the complex phase of coating until the formulation defined for packaging vompe obtained.

Radhakrishnan and Dr B. The biotechnological active ingredient rhNGF is produced here and marketed in Italy and Europe for the treatment of neurotrophic keratitis.

This phase is followed by packaging in boxes, wrapping and pallets. The 3D structure of rhNGF is a non-covalent dimer with three intra-molecular disulphide bridges. The pro-sequence is further cleaved during the production process by enzymatic hydrolysis.

In this respect, over the last ten years, the Biotech Formulation rompe has managed to develop partnerships in the public and private domains, becoming a point of reference for transverse research projects. In the turnover was million is focused both on the development of pharmaceuticals for therapeutic needs as yet unfulfilled, in the areas of ophthalmology, oncology, diabetes and organ transplant, as well as in the creation of innovative industrialisation processes of these.

The production process for granules includes an initial phase of dispensing weighing of the raw materials active ingredient and excipients.